AZT, 3TC & nelfinavir

DonateNow
Print this article

AZT, 3TC & nelfinavir

AIDS Treatment Update, No. 44, August 1996
Edward King


The protease inhibitor nelfinavir, currently undergoing trials at two hospitals in London, exerts an extremely potent anti-HIV effect in combination with AZT and 3TC, reported Dr David Ho.

The study recruited twelve anti-retroviral naive patients with high initial viral load (100,000 copies/ml) and an average CD4 count of 245. One participant dropped out because of diarrhoea, known to be a common side-effect of nelfinavir.

The remaining eleven had CD4 count increases averaging 95, their viral load fell to undetectably low levels (below 25 copies/ml) after 16 weeks of treatment, and infectious virus could not be grown in culture from their blood cells. The average reduction was 3.96 log - one of the best yet reported for an anti-viral combination. After twenty weeks several cases of candidiasis, neuropathy, folliculitis and oral hairy leucoplakia had cleared up (LB.B.6031).


960810
ATU4410


Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1996 - AIDS Treatment Update. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. NAM Publications 16a Clapham Common Southside, London, England SW4 7AB; TEL: 01-71-627-3200 (from outside the UK: +44-171-627-3200); FAX: 01-71-627-3101 (from outside the UK: +44=171-627-3101)  info@nam.org.uk  http://www.nam.org.uk


This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1996. AEGIS.